Cerevel Therapeutics Holdings, Inc.

NasdaqCM:CERE Rapporto sulle azioni

Cap. di mercato: US$8.2b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Cerevel Therapeutics Holdings Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Cerevel Therapeutics Holdings has a total shareholder equity of $564.5M and total debt of $451.9M, which brings its debt-to-equity ratio to 80.1%. Its total assets and total liabilities are $1.1B and $562.9M respectively.

Informazioni chiave

80.1%

Rapporto debito/patrimonio netto

US$451.92m

Debito

Indice di copertura degli interessin/a
ContantiUS$846.29m
Patrimonio nettoUS$564.46m
Totale passivitàUS$562.89m
Totale attivitàUS$1.13b

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Cerevel Therapeutics Holdings (NASDAQ:CERE) Has Debt But No Earnings; Should You Worry?

Apr 30
Cerevel Therapeutics Holdings (NASDAQ:CERE) Has Debt But No Earnings; Should You Worry?

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Shares Could Be 23% Above Their Intrinsic Value Estimate

Jan 02
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Shares Could Be 23% Above Their Intrinsic Value Estimate

Cerevel overweight at Wells Fargo due to candidates with blockbuster potential

Sep 26

Cerevel Therapeutics prices $300M in notes offering, $254M in stock offering

Aug 12

Cerevel Therapeutics GAAP EPS of -$0.61 misses by $0.13

Aug 01

Cerevel: The Next Big Thing In CNS Disease? Maybe If The Market Wasn't So Crowded

Jul 08

Cerevel Therapeutics: Pfizer's Neurology Spin-Off

Jul 14

We're Not Very Worried About Cerevel Therapeutics Holdings' (NASDAQ:CERE) Cash Burn Rate

Jun 09
We're Not Very Worried About Cerevel Therapeutics Holdings' (NASDAQ:CERE) Cash Burn Rate

Is Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Popular Amongst Institutions?

Jan 29
Is Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Popular Amongst Institutions?

Cerevel Therapeutics (CERE) Investor Presentation - Slideshow

Nov 18

Cerevel Therapeutics reports Q3 results

Nov 16

Analisi della posizione finanziaria

Passività a breve termine: CERE's short term assets ($859.6M) exceed its short term liabilities ($84.1M).

Passività a lungo termine: CERE's short term assets ($859.6M) exceed its long term liabilities ($478.8M).


Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: CERE has more cash than its total debt.

Riduzione del debito: CERE's debt to equity ratio has increased from 7.4% to 80.1% over the past 5 years.


Bilancio


Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: CERE has sufficient cash runway for more than a year based on its current free cash flow.

Previsione Cash Runway: CERE has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 31.2% each year.


Scoprire le aziende sane